# Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)

> **NCT00797940** · PHASE2 · WITHDRAWN · sponsor: **Sophiris Bio Corp**

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** IL-4PE

## Key facts

- **NCT ID:** NCT00797940
- **Lead sponsor:** Sophiris Bio Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-01
- **Primary completion:** 2010-12
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No funding for study
- **Last updated:** 2012-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00797940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00797940, "Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00797940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*